Dr. Thomas M. Rinderknecht Chairs Supervisory Board Of GANYMED Pharmaceuticals AG

MAINZ, GERMANY -- (MARKET WIRE) -- October 11, 2006 -- GANYMED Pharmaceuticals AG, a privately held cancer antibody company, announces the appointment of Dr. Thomas M. Rinderknecht as new Chairman of the Supervisory Board and the election of Dr. Alfred Scheidegger as new member of the Supervisory Board. Mr. Rinderknecht also invested an undisclosed amount in a second closing of GANYMED's Series B round in July 2006. He replaced Mr. Felix Hofstetter as Chairman of the Supervisory Board, who joined Migros Ostschweiz as Head of Finance, and Alfred Scheidegger replaced Dr. John Ryan, who joined Cambridge (Mass) based Aveo as Chief Medical Officer.

Back to news